Tradestie Institutional Equity Comparison Engine

BDTX vs LYRA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BDTX Overall Edge

BDTX Captures Institutional Edge (4โ€“0 Pillars ยท 8โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Black Diamond Therapeutics, Inc. Common Stock (BDTX) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, BDTX trades at 8.3x Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus LYRA at N/M Forward P/E and -25032.0% operating margin (-87.2% YoY). In options structure, BDTX sits in BREAKDOWN (55th %ile IV; Dealer Gamma Walls on Pro) against LYRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner BDTX
BDTX 8.3x vs LYRA N/M Fwd P/E
Growth & Margin Winner BDTX
Op Margin 0.0% vs -25032.0% ยท YoY +0.0% vs -87.2%
Momentum & Technical Winner BDTX
1Y -64.8% vs -94.3% ยท 52W Pos 1% vs 1%
Options & Structure Winner BDTX
BREAKDOWN (55th %ile IV) vs UNCLASSIFIED (N/A IV)
BDTX NASDAQ
Black Diamond Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.41
-7.84% 1D
Market Cap $84.5M
1M Return -22.1%
1Y Return -64.84%
Forward P/E 8.3x
Unified AI Score
56.1 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 70.0 Mom 50.0
LYRA NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap $2.3M
1M Return -62.5%
1Y Return -94.34%
Forward P/E N/M
Unified AI Score
52.2 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 50.0 Mom 59.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BDTX -64.84% LYRA -94.34% Spread: +41.75 pp (BDTX Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period BDTX Revenue LYRA Revenue BDTX Op. Margin LYRA Op. Margin Margin Edge
FY2021 N/A $0M N/A -15303.5% LYRA
FY2022 N/A $0M N/A -4131.0% LYRA
FY2023 N/A $0M N/A -4308.1% LYRA
FY2024 N/A $0M N/A -6280.8% LYRA
FY2025 $70M $0M 17.9% -7794.5% BDTX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BDTX (8) vs LYRA (1)
Institutional Metric BDTX LYRA Criterion Row Winner
Market Capitalization Scale $84.5M $2.3M Larger Scale BDTX
Trailing P/E Ratio Valuation 8.3x N/M Lower Multiple BDTX
Forward P/E Ratio Valuation 8.3x N/M Lower Multiple BDTX
Revenue Growth (YoY) Growth +0.0% -87.2% Higher Growth BDTX
Operating Margin (TTM) Profitability 0.0% -25032.0% Higher Margin BDTX
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -41.1% -404.5% Higher ROE BDTX
52-Week Range Position Momentum 1% ($1โ€“$4) 1% ($0โ€“$38) Stronger Trend LYRA
Beta / 30D Volatility Risk Regime 1.80ฮฒ ยท 111% Vol 0.33ฮฒ ยท 248% Vol Lower Realized Risk BDTX
Unified Institutional Score Composite Signal 56.1 / 100 (HOLD) 52.2 / 100 (HOLD) Higher Composite BDTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BDTX vs LYRA Buy Guide
BDTX BREAKDOWN
125d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 55th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live BDTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
LYRA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live LYRA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BDTX nor LYRA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.